文献速递脊柱关节炎

司库奇尤单抗不损害流感疫苗免疫原性应答

Secukinumab does not impair the immunogenic response to the influenza vaccine in patients.
PubMed 文献 · RMD Open · 2019-09-03

研究纳入17例接受司库奇尤单抗治疗的银屑病关节炎或强直性脊柱炎患者和13名健康对照,接种2017-2018年北半球三价灭活流感疫苗后评估血凝抑制抗体应答。结果显示两组抗体倍数升高和血清转化率相似,司库奇尤单抗未影响对流感疫苗的免疫应答。

要点

  • 司库奇尤单抗治疗患者对流感疫苗的抗体应答与健康对照相似。
  • 两组对H3N2株应答均较差,抗体升高<1.5倍。
  • 血清转化率在两组间相似,司库奇尤单抗不影响疫苗应答。

核心结论

  • 本研究中司库奇尤单抗对流感疫苗的免疫原性应答无影响。

研究设计与样本

  • 纳入17例接受司库奇尤单抗治疗的银屑病关节炎或强直性脊柱炎患者和13名健康对照,随访33±8天。
  • 所有参与者接种2017-2018年北半球季节性三价灭活流感疫苗,含A/Michigan/45/2015 (H1N1)pdm09样、A/Hong Kong/4801/2014 (H3N2)样和B/Brisbane/60/2008样病毒。
  • 采用血凝抑制法检测接种前和接种后至少4周针对三个疫苗株的基线抗体滴度,应答定义为抗体滴度>4倍升高。

主要发现

  • 患者和对照针对抗H1N1的中位抗体倍数升高分别为4.6倍和4.0倍,针对抗B抗体分别为3.7倍和5.3倍。
  • 两组对H3N2株应答均较差,抗体升高<1.5倍。
  • 两组血清转化率相似。
  • 司库奇尤单抗未影响疫苗应答:H1N1相对风险1.09(95%CI 0.58-2.07),H3N2相对风险1.53(95%CI 0.15-15.0),B株相对风险0.72(95%CI 0.32-1.83)。

临床怎么用

  • 接受司库奇尤单抗治疗的风湿免疫病患者可正常接种流感疫苗,无需担心免疫应答受损。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether immunological response to influenza vaccination is impaired in patients who are receiving secukinumab. PATIENTS AND METHODS: Subjects suffering from psoriatic arthritis or ankylosing spondylitis who were receiving treatment with secukinumab and healthy volunteers were included.All participants received seasonal inactivated trivalent influenza vaccine recommended by the WHO in the 2017-2018 northern hemisphere influenza season, which contained an A/Michigan/45/2015 (H1N1)pdm09-like virus, an A/Hong Kong/4801/2014 (H3N2)-like virus and a B/Brisbane/60/2008-like virus.Haemagglutination inhibition was used to evaluate basal antibody (Ab) titres against the three influenza vaccine virus strains just before vaccination and at least 4 weeks after the vaccine administration. Response to vaccine was considered as >4-fold increases in Ab titre. RESULTS: Thirty subjects, 17 patients and 13 healthy controls, with a follow-up duration of 33±8 days, were analysed. There were no demographic differences between groups. Patients and controls achieved a median of 4.6-fold and 4.0-fold increases, respectively, for anti H1N1 and almost 4.0 (3.7) for patients and 5.3 for controls for anti-B Ab. Both groups presented a poor response against H3N2, with <1.5-fold increase. Seroconversion rates were similar in both groups. Secukinumab did not influence the response to the influenza vaccine (relative risk: 1.09 (95% CI 0.58 to 2.07) for H1N1, RR: 1.53 (95% CI 0.15 to 15.0) for H3N2 and RR: 0.72 (95% CI 0.32 to 1.83) for B strain). CONCLUSION: In our study, secukinumab has no effect on the immunogenic response to the influenza vaccine.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Richi P, Martín MD, de Ory F, et al. Secukinumab does not impair the immunogenic response to the influenza vaccine in patients. RMD Open. 2019. PMID: 31565246. doi:10.1136/rmdopen-2019-001018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。